Article

HPV vaccine-induced cross-neutralising antibodies target complex epitopes on the major capsid protein

2016-01-01

Abstract excerpt

The current human papillomavirus (HPV) vaccines consist of major capsid protein (L1) virus-like particles (VLP) and target the two most prevalent oncogenic genotypes, HPV16 and HPV18. Prophylactic HPV vaccination is highly effective at preventing HPV16 and HPV18 infection and associated cervical disease, with type-specific neutralising antibodies thought to be the immune mediators of vaccine type protection. A deg...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5bd9928c-d67b-5e3a-b861-4123806426c5
DOI: 10.25560/33740

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

HPV vaccine-induced cross-neutralising antibodies target complex epitopes on the major capsid proteinDOI 10.25560/33740Read

L2 epitope presenting virus-like particles as broad- spectrum vaccine candidates targeting genus beta human papillomavirusesSemantic proximity Read

Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.Semantic proximity Read

Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.Semantic proximity Read

A Chimeric 18L1-45RG1 Virus-Like Particle Vaccine Cross-Protects against Oncogenic Alpha-7 Human Papillomavirus TypesSemantic proximity Read

Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.Semantic proximity Read

Rational design of a cross-type HPV vaccine through immunodominance shift guided by a cross-neutralizing antibodySemantic proximity Read

Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like ParticlesSemantic proximity Read

Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes.Semantic proximity Read

Human Papillomavirus (HPV) Vaccines: Limited Cross‐Protection against Additional HPV TypesSemantic proximity Read

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated DiseasesSemantic proximity Read

Human papillomavirus vaccines and the potential for cross-protection between related HPV typesSemantic proximity Read

HPV16 neutralizing monoclonal antibodies show evidence for common developmental pathways and public epitopesSemantic proximity Read